Monday, March 2, 2026
Novo Nordisk to invest €432m in Athlone manufacturing site
Novo Nordisk plans to expand manufacturing capacity for oral GLP-1 therapies in Europe. On 2 March 2026, the company announced a €432 million investment in its tabletting facility in Monksland, Athlone, Ireland.
Added capacity for current and future GLP-1 therapies
According to the company, the expansion is intended to provide additional manufacturing capacity for existing and future GLP-1 treatments. The Athlone site focuses on oral products and is expected to strengthen supply for markets outside the US.
Upgrade and retrofit of the existing facility
The investment is set to fund upgrades and retrofit work at the current plant. The overall project covers the 45-acre site (about 18 hectares). Construction has already started, with completion planned in phases from the end of 2027 through 2028.
Jobs and site footprint
The facility currently employs 260 people. Novo Nordisk expects the project to create up to 500 construction jobs during the build-out.
Company background
Novo Nordisk is headquartered in Denmark and focuses on treatments for serious chronic diseases. The company employs about 68,800 people globally and markets its products in around 170 countries.
Related articles
GSK agrees to acquire 35Pharma, adding pulmonary hypertension asset HS235
GSK has agreed to acquire Canada’s 35Pharma for $950m in cash, gaining HS235, an activin signalling inhibitor being developed for pulmonary hypertension.
Novo Nordisk partners with Vivtex on oral biologics
Novo Nordisk and Vivtex will work on oral biologics for obesity and diabetes. Vivtex is eligible for up to US$2.1 billion plus tiered royalties.
Merck reshapes business ahead of Keytruda patent expiry
Merck & Co. is splitting operations into two divisions to prepare for Keytruda’s 2030 patent expiry and to broaden its portfolio.
medac Group exits diagnostics business to focus on pharma
medac Group is divesting its diagnostics activities via a management buy-out to focus on pharma. The business will continue as mevida Diagnostika.
Hameln to host second nursing congress on the future of care
Sana Klinikum Hameln-Pyrmont will host the “Pflege bewegt” nursing congress on 16 April 2026 in Hameln, focusing on future nursing practice.
DMEA sparks Award 2026 opens call for digital health theses
DMEA has opened applications for the sparks Award 2026, honouring bachelor’s and master’s theses on healthcare digitalisation. Deadline: 31 January 2026.
WEFRA MEDIAPLUS GLOBAL HEALTH Sets New Standards in Healthcare Media
With WEFRA MEDIAPLUS GLOBAL HEALTH, Mediaplus Group and WEFRA LIFE GROUP combine their strengths to deliver scalable, international healthcare campaigns. The joint venture connects global strategies with strong local execution.
New care concept strengthens outpatient follow-up for cardiac patients
Novartis Germany and the Ambulatory Heart Center Kassel are launching a new outpatient care concept to support structured follow-up care for cardiac patients, with a focus on LDL cholesterol. The goal is to sustainably reduce risk factors through standardized treatment pathways.